The OpenFold Consortium Names Dr. Jan Domanski as Senior Science Lead to Drive the Next Generation of Open Source AI Models for Structural Biology and Drug Discovery




The OpenFold Consortium Names Dr. Jan Domanski as Senior Science Lead to Drive the Next Generation of Open Source AI Models for Structural Biology and Drug Discovery

DAVIS, Calif.–(BUSINESS WIRE)–The OpenFold Consortium, a leading open-science initiative developing AI foundation models for biomolecular structure prediction, today announced that Dr. Jan Domanski has joined the consortium as senior science lead. In this role, Dr. Domanski will spearhead scientific innovation, engineering excellence, and ecosystem growth as OpenFold advances its mission to democratize access to high-performance AI models for structural biology and drug discovery. He will work closely with Dr. Jennifer Wei, OpenFold’s senior technical lead, and a global network of academic and industry contributors to build an open, modular software stack that links state-of-the-art AI models with rich experimental and simulation data to improve model generalization and robustness for drug discovery.

“Dr. Domanski embodies the spirit of OpenFold: a deep scientific understanding of proteins coupled with professional engineering expertise and a builder’s mindset,” said Dr. Woody Sherman, Chair of the OpenFold Executive Committee. “His experience architecting AI-driven platforms to drive drug discovery programs from concept to clinic will be invaluable as we expand OpenFold’s reach beyond structure prediction toward accurate biomolecular interactions, dynamics, and generative design.”

As part of the Open Molecular Software Foundation (OMSF), OpenFold is committed to advancing open and reproducible science across molecular modeling. Following the preview release of OpenFold3, an open-source model capable of predicting protein, nucleic acid, and small-molecule interactions with near–AlphaFold 3 accuracy, the consortium is now focused on building the next generation of foundation models that integrate AI and physics-based approaches for biomolecular understanding and drug discovery.

“OpenFold has already proven that open collaboration can match or exceed the capabilities of proprietary AI models,” said Dr. Domanski. “The next phase is to make these models truly usable and extensible—to enable every scientist, from academia to biotech, to contribute, adapt, and apply them across new frontiers of biology and medicine.”

Dr. Domanski brings over a decade of experience at the intersection of machine learning, molecular simulation, and scientific software development. With a Ph.D. obtained through the NIH Oxford-Cambridge Scholars Program, a joint program between the University of Oxford and the NIH, he studied membrane protein folding under the supervision of Professors Mark Sansom and Philip Stansfeld at Oxford and Dr. Robert Best at the NIH. Dr. Domanski has dedicated his career to building tools that bridge cutting-edge computation with experimental science to accelerate drug discovery and innovation in the life sciences. Dr. Domanski also worked at D. E. Shaw Research where he applied the long timescale molecular dynamics simulations to small-molecule discovery, understanding the relationship between protein structure and function.

Prior to joining OpenFold, Dr. Domanski was Founder and CTO of Labstep, a pioneering digital lab automation platform acquired by STARLIMS. In 2022, Dr. Domanski joined Charm Therapeutics, where he was among the first five employees. There, he built and scaled the company’s machine learning and software engineering teams, collaborated closely with medicinal chemists and structural biologists, and led the development of DragonFold, a state-of-the-art co-folding model that powered Charm’s integrated small-molecule discovery platform. This technology contributed to the identification of CHM-029, Charm’s next-generation menin inhibitor expected to enter the clinic in 2026.

The OpenFold Consortium is supported by member organizations and philanthropic partners. By investing in OpenFold today, you have a unique opportunity to shape the future of open, trustworthy AI infrastructure in the life sciences, ensuring that state-of-the-art models remain freely accessible to scientists everywhere.

If you or your organization are excited to support open, community-driven AI for science, please contact Dr. Mallory Tollefson at mallory.tollefson@omsf.io. Your support helps accelerate discovery, empower the next generation of scientists, and sustain critical tools that the entire biomedical ecosystem relies on.

Contacts

Media Contact:

Mallory Tollefson, Ph. D.

OpenFold Consortium

mallory.tollefson@omsf.io

Atelerix Enters Agreement with Cherry Biotech to Integrate Non-cryogenic Transport Solutions With Advanced Organoid Models




Atelerix Enters Agreement with Cherry Biotech to Integrate Non-cryogenic Transport Solutions With Advanced Organoid Models

Partnership brings together proven non-cryogenic biosample preservation technology and advanced organoid models to support growth in preclinical research and biotech sectors

NEWCASTLE, England–(BUSINESS WIRE)–Atelerix, a biotech company revolutionising cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced it has entered a partnership with Cherry Biotech, a French company specialising in organ-on-chip and organoid technologies for biomedical research.

The initial agreement will explore the integration of Atelerix’s patented hydrogel technology with Cherry Biotech’s advanced 3D organoid models to facilitate global extended-duration shipment. In collaboration, the companies aim to improve the reliability and consistency of transporting these temperature-sensitive materials without the complications of cold-chain logistics, enabling significant growth and expanded customer access to high-quality, human-relevant preclinical data worldwide. Through an initial 12-month trial period, both parties will validate their strategic and technical alignment, establishing the groundwork for a scalable, long-term commercial partnership.

Cherry Biotech’s in vitro product range combine AI analysis, high-resolution live imaging and precisely controlled organoid culture to better predict the efficacy and safety of drugs, generating real life-like preclinical data. As part of the partnership, Atelerix’s hydrogel technology will also be validated for the stable shipment of Cherry Biotech’s recently released organoidPlate – an advanced multiwell plate with ready to use organoids for adipose tissue, breast cancer, liver and lung, which is now available for worldwide shipping.

The MoU builds on a test period whereby Cherry Biotech demonstrated strong performance of Atelerix’s biosample preservation technology across multiple organ models, preserving membrane integrity and biological function at ambient or controlled temperatures.

Alastair Carrington, CEO, Atelerix, commented: “This latest partnership with Cherry Biotech is a key step in expanding our commercial traction, broadening market reach, and increasing visibility for Atelerix’s solutions. It is fantastic to work alongside such an innovative CRO, we are delighted that our preservation technology has already proven itself in delivering organoid models reliably and hassle-free to researchers worldwide. This partnership provides key validation, reinforcing the potential of ambient logistics to support the adoption of assay-ready animal model alternatives, advancing drug testing and better predicting human responses.”

Pierre Gaudriault, Chief Business Development Officer, Cherry Biotech, added: “Partnering with Atelerix strengthens our ability to deliver cutting-edge organoid models to researchers in pharma and academia worldwide. The hydrogel preservation technology maintains cell viability for days at room temperature, removing cold-chain constraints and reducing environmental footprint. This innovation brings unprecedented convenience and reliability to our customers. In short, Aterelix is making easy global shipping for our product possible.”

Contacts

Media
Jake Brown

jake.brown@zymecommunications.com

GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe




GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe

ATHENS, Greece–(BUSINESS WIRE)– 

ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY

GENESIS Pharma, a regional biopharma company focused on the commercialization of innovative medicines in Central and Eastern Europe, announces an exclusive agreement with Otsuka Pharmaceutical Europe Ltd. (OPEL), the European operation of global healthcare company Otsuka Pharmaceutical Co., Ltd., for donidalorsen. Under the terms of the agreement, GENESIS Pharma will exclusively distribute and commercialize donidalorsen in fourteen markets: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia.

In November 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for donidalorsen in the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. The CHMP opinion is currently under review by the European Commission (EC), to determine donidalorsen’s authorisation in the European Union (EU). Donidalorsen is an investigational RNA-targeted medicine designed to reduce the production of prekallikrein (PKK), interrupting the pathway that leads to HAE attacks^1,2.

Mr. Constantinos Evripides, Managing Director of GENESIS Pharma stated: “We are excited to expand our international partnerships in the CEE region through this new collaboration with Otsuka Pharmaceutical Europe Ltd., a company focusing on some of the world’s unresolved health issues. The addition of donidalorsen to our robust rare disease medicines portfolio is another step forward in our mission to support patients with rare and serious conditions, ensuring access to innovative treatments in our region. Thus, we look forward to the forthcoming decision from the European Commission.”

Donidalorsen was discovered and developed by Ionis Pharmaceuticals, Inc. (Ionis). In December 2023, Otsuka acquired exclusive rights to commercialize donidalorsen in Europe through a licensing agreement with Ionis.

About Hereditary Angioedema (HAE)

HAE is a rare, chronic and potentially life-threatening genetic condition that involves recurrent, unpredictable attacks of swelling episodes that can affect the extremities, face, abdomen, genitals and even the larynx, posing serious risk for patients.³ Symptoms of HAE usually begin in childhood or early adulthood, with some individuals experiencing their first episodes as young as two years old.^4,5 HAE imposes a significant burden on patients and their families, with unpredictable and often debilitating attacks which can disrupt daily life, limit activities and reduce productivity at work or school. ^6-8 HAE is most commonly caused by an inherited deficiency or dysfunction of C1 esterase inhibitor, which leads to uncontrolled activation of the plasma kallikrein-kinin system and excessive production of bradykinin.^5,9,10 Approximately 15,000 individuals are living with HAE in Europe with a worldwide prevalence estimated to be 1 in 50,000.^3,5,11

About GENESIS Pharma

GENESIS Pharma is a regional biopharma company focused on the commercialization of innovative biopharmaceutical products targeting severe and rare diseases in Central and Eastern Europe. Established in 1997, GENESIS Pharma was among the first pharmaceutical companies in Europe to specialize in the marketing, sales and distribution of biopharmaceutical products. GENESIS Pharma maintains a strong portfolio in therapeutic areas with high unmet medical need through long standing strategic alliances with some of the leading global biopharma companies. For more information, please visit www.genesispharma.com and follow us on LinkedIn.

REFERENCES

1. Riedl MA, et al. N Engl J Med 2024;391(1):21–31.
2. Riedl MA, et al. J Allergy Clin Immunol Pract 2025;13(9):2381–2389.
3. Raasch J, et al. World Allergy Organ J 2023;16(6):100792.
4. Busse P, et al. J Allergy Clin Immunol Pract 2021;9(1):132–150.e3.
5. Maurer M, et al. Allergy 2022;77(7):1961–1990.
6. Aygoren-Pursun E, et al. Orphanet J Rare Dis 2014;9:99.
7. Chong-Neto HJ, World Allergy Organ J 2023;16(3):100758.
8. Mendivil J, et al. Orphanet J Rare Dis 2021;16:94.
9. Santacroce R, et al. Review J Clin Med 2021:10(9):2023.
10. Longhurst HJ, Bork K. Br J Hosp Med (Lond) 2019:2;80(7):391–398.
11. Lumry WR. Hereditary angioedema: the economics of treatment of an orphan disease. Front Med (Lausanne). 2018;5:22.

Contacts

For more information, please contact:
Natalia Karahaliou, Communications Manager

nkarahaliou@genesispharma.com
+30 210 87 71 605

LEO Pharma Submits Adolescent Label Expansion Application for Anzupgo® to EMA




LEO Pharma Submits Adolescent Label Expansion Application for Anzupgo® to EMA

• LEO Pharma has submitted a label expansion application to EMA to expand Anzupgo® (delgocitinib) cream to adolescent patients (12–17 years) with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate – the application has been accepted for review.
• The application is supported by results from DELTA TEEN, a phase 3 trial investigating efficacy and safety of Anzupgo® in adolescents with moderate to severe chronic hand eczema (CHE).¹
• The label expansion submission for adolescent patients demonstrates LEO Pharma’s commitment to investigating use within relevant sub-populations where treatments can help make a fundamental difference for patients with skin diseases.

BALLERUP, Denmark–(BUSINESS WIRE)–NOT FOR UK USE – NOT INTENDED FOR UK MEDIA

LEO Pharma A/S, a global leader in medical dermatology, today announced submission of a label expansion application to the European Medicines Agency (EMA) to expand the use of Anzupgo^® (delgocitinib) cream to adolescents aged 12 to 17 years, living with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate in the European Union. The label expansion application has been accepted for review by EMA.

“With the submission of our label expansion application for Anzupgo^®, LEO Pharma is reinforcing our commitment aiming at improving the lives of patients with skin diseases,” said Sophie Lamle, Executive Vice President, Development. “Adolescents living with this debilitating disease, in the EU, currently have no treatment options specifically approved for moderate to severe CHE, and we are proud to take this important step toward addressing that unmet need. Backed by our global expertise and dedication to innovation, we are excited about the potential to bring a treatment that can help make a meaningful difference in the everyday lives of adolescent patients.”

Research on adolescents with CHE shows that the disease can impact far beyond the skin. CHE can have considerable negative impact on quality of life, affecting psychosocial well-being, school performance and participation in leisure activities.²

The label expansion application is supported by results from DELTA Teen, a phase 3 trial with Anzupgo^® (delgocitinib) 20mg/g cream, that investigated the efficacy and safety of twice-daily applications of Anzupgo^® compared with cream vehicle in adolescents 12-17 years of age with moderate to severe CHE for whom topical corticosteroids are inadequate or inappropriate .¹ The detailed results were presented as a late breaking presentation at European Academy of Dermatology and Venereology 2025 in Paris, France.

Anzupgo^® is currently approved in adult patients with moderate to severe CHE for whom topical corticosteroids are inadequate or inappropriate in the European Union³, as well as several additional markets, including the US, Switzerland and the UK.

About Chronic Hand Eczema

Chronic Hand Eczema (CHE) is defined as hand eczema (HE) that lasts for more than three months or relapses twice or more within a year.^4,5 CHE is one of the most common skin diseases of the hands with a global prevalence rate of approximately 4.7%.^6,7 In a substantial number of patients, HE can develop into a chronic disease.⁶ CHE is a fluctuating disease characterized by itch and pain, and patients may experience signs such as erythema, scaling, lichenification, hyperkeratosis, vesicles, edema, and fissures on hands and wrists.⁸

CHE has been shown to cause psychological and functional burdens that impact patient quality of life,^9,10 with approximately 70% of individuals who live with severe CHE admitting to problems in performing everyday activities, and suffering disruption in their daily life due to the condition.¹¹ Furthermore, careers and earning potential have also been shown to be impacted by the burden of living with CHE.¹²

About Anzupgo^® (delgocitinib) Cream

Anzupgo^® cream is a topical pan-Janus kinase (JAK) inhibitor for the treatment of moderate to severe CHE in adults. It inhibits the activation of JAK-STAT signaling, which plays a key role in the pathogenesis of CHE.¹³

Anzupgo^® is approved in the European Union, United Kingdom, Switzerland, Canada, Australia, South Korea, and the United Arab Emirates for the treatment of moderate to severe Chronic Hand Eczema (CHE) in adults for whom topical corticosteroids are inadequate or inappropriate. Anzupgo^® cream is also under investigation in other markets.

Anzupgo^® (delgocitinib) cream is FDA approved in the U.S. for moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable. Use of Anzupgo^® in combination with other JAK inhibitors or potent immunosuppressants is not recommended by the U.S. FDA.¹⁴

Please click here for full U.S. Prescribing Information, including Patient Information and Instructions for Use.

In 2014, LEO Pharma obtained the exclusive rights to develop and commercialize delgocitinib for topical use in dermatological indications worldwide, excluding Japan, where Shionogi Inc. owns the rights.

About the DELTA TEEN Trial

DELTA TEEN was a 16-week, phase 3, randomized, double-blind, vehicle-controlled, parallel group, multi-site trial to evaluate the efficacy and safety of twice-daily applications of Anzupgo^® compared with cream vehicle in adolescents 12-17 years of age with moderate to severe CHE for whom topical corticosteroids are inadequate or inappropriate.¹

The primary endpoint of DELTA TEEN was the Investigator’s Global Assessment for chronic hand eczema treatment success (IGA-CHE TS) at Week 16. Treatment success was defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with at least a two-step improvement from baseline.¹

About LEO Pharma

LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. Together, we reach far beyond the skin.

For more information, visit www.leo-pharma.com.

References

1. ClinicalTrials.gov. National Library of Medicine (U.S.). Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema (DELTA TEEN). Identifier: NCT05355818. https://clinicaltrials.gov/study/NCT05355818.
2. Haft MA, Park HH, Lee SS, Sprague JM, Eichenfield LF. Pediatric chronic hand eczema: Epidemiology, clinical presentation, and management. JAAD Int. 2023;11:165-173.
3. European Medicines Agency. Anzupgo 20 mg/g cream: summary of product characteristics. Amsterdam: EMA; 2024 [updated 2025 Jan 22; cited 2025 Dec 9]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/anzupgo
4. Lynde C, Guenther L, Diepgen TL, et al. Canadian hand dermatitis management guidelines. J Cutan Med Surg . 2010;14(6):267-284. Erratum in: J Cutan Med Surg. 2011 Nov-Dec;15(6):360.
5. Diepgen TL, et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges. 2015 Jan;13(1):e1–22.
6. Bissonnette R, et al. Redefining treatment options in chronic hand eczema (CHE). JEADV. 2010;24;1–20.
7. Apfelbacher C, Bewley A, Molin S, et al. Prevalence of chronic hand eczema in adults: a cross-sectional survey of over 60 000 respondents from the general population of Canada, France, Germany, Italy, Spain and the UK. Presented at the 2024 European Society of Contact Dermatitis (ESCD) congress; September 04-07 2024; Dresden, Germany. Poster presentation #3
8. Thyssen JP, Schuttelaar MLA, Alfonso JH, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis. 2022;86(5):357-378.
9. Grant L, Seiding Larsen L, Burrows K, et al. Development of a Conceptual Model of Chronic Hand Eczema (CHE) Based on Qualitative Interviews with Patients and Expert Dermatologists. Adv Ther. 2020;37(2):692-706.
10. Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984-991.
11. Cortesi PA, Scalone L, Belisari A, et al. Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. Contact Dermatitis. 2014;70(3):158-168.
12. Voorberg AN, Loman L, Schuttelaar MLA. Prevalence and Severity of Hand Eczema in the Dutch General Population: A Cross-sectional, Questionnaire Study within the Lifelines Cohort Study. Acta Derm Venereol. 2022;102:adv00626.
13. Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges. Ther Clin Risk Manag. 2020;16:1319-1332. Erratum in: Ther Clin Risk Manag. 2021 Mar 18;17:233.
14. ANZUPGO^® (delgocitinib) cream. Prescribing Information. FDA. July 2025.

MAT-88642 December 2025

Contacts

Jes Broe Frederiksen

Global Corporate Communication

+45 53 60 59 48

jebfe@leo-pharma.com

Christian Bundgaard

Global Corporate Communication

+45 53 74 88 49

chbun@leo-pharma.com

Mitsubishi Electric Achieves World’s First Mechanism for Elucidating Ozone Oxidation Enhanced with Negative Ions




Mitsubishi Electric Achieves World’s First Mechanism for Elucidating Ozone Oxidation Enhanced with Negative Ions

Reduces surface-bound viruses, bacteria and odors for safe, secure, and comfortable indoor environment

TOKYO–(BUSINESS WIRE)–Mitsubishi Electric Corporation (TOKYO: 6503) announced today that in collaboration with Professor Toshiaki Kamachi and colleagues from the School of Life Science and Technology at Institute of Science Tokyo (Science Tokyo) they have achieved the world’s first mechanism for elucidating the combined use of negative ions to enhance the oxidative action of ozone. In their joint study, they discovered that dissolving negative ions in the moisture surrounding viruses and other microorganisms lowers the pH due to nitrate-containing components derived from the negative ions, which in turn enhances the oxidative action of ozone in the moisture, enabling a strong reduction of viruses and bacteria even at low ozone concentrations. Mitsubishi Electric confirmed the reduction of bacteria and odors in low ozone concentrations of 50 parts per billion (ppb) in addition to specific viruses reported previously.

Buildings are becoming more airtight and better insulated, raising concerns about inadequate indoor ventilation and unhygienic conditions. Ozone’s oxidative action has traditionally been used to maintain indoor hygiene, but ozone alone has faced challenges in terms of the durability and stability of its sanitizing effects. It is also known that ozone’s reduction of viruses and bacteria increases when used with negative ions and varies with pH. However, the specific chemical species of the negative ions and their pH-controlling effects had not been clarified.

For the full text, please visit: www.MitsubishiElectric.com/news/

Contacts

Customer Inquiries
Advanced Technology R&D Center

Mitsubishi Electric Corporation

Fax: +81-6-6497-7285

www.MitsubishiElectric.com/ssl/contact/company/rd/form.html
www.MitsubishiElectric.com/en/about/rd/

Media Inquiries
Takeyoshi Komatsu

Public Relations Division

Mitsubishi Electric Corporation

Tel: +81-3-3218-2332

prd.gnews@nk.MitsubishiElectric.co.jp
www.MitsubishiElectric.com/en/pr/

Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors




Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Company to host webcast Monday, December 15, 2025 at 8:30 a.m. ET

BOTHELL, Wash.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the company will host a conference call and webcast on Monday, December 15, 2025 at 8:30 am ET to disclose the topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an investigational, oral, once-daily gamma secretase inhibitor, in patients with progressing desmoid tumors.

Webcast, Presentation Slides and Conference Call Information

Immunome will host a webcast and conference call on Monday, December 15, 2025, at 8:30 a.m. ET / 5:30 a.m. PT to discuss the Phase 3 RINGSIDE trial topline results. A live webcast, which will include presentation slides, can be accessed using this link or by visiting the Events and Presentations section of the Immunome website at https://investors.immunome.com/events. The conference call can be accessed by clicking on the call link and completing the online registration form, which will enable the selection of a dial-in number or callback from the system. A live question-and-answer session will follow the prepared remarks. Participants wishing to ask a question must do so via the conference call; the webcast will be listen-only. After the live webcast, the event will remain archived on the Immunome website for 90 days. 

About Immunome, Inc.

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugate therapies. Our pipeline includes varegacestat, a late-clinical stage GSI; IM-1021, a clinical-stage ROR1 ADC; and IM-3050, a FAP-targeted radiotherapy that recently received IND clearance. We are also advancing a broad portfolio of early stage ADCs pursuing undisclosed solid tumor targets. For more information, visit www.immunome.com.

Contacts

Investor Contact:

Max Rosett

Chief Financial Officer, Immunome

investors@immunome.com

Media Contact:
Nicole Foderaro

Real Chemistry

media@immunome.com

GMP Cytokine Market and Competition Outlook to 2031: Growing at 8.4% CAGR, Led by Bio-Techne, PeproTech, CellGenix Among Others – ResearchAndMarkets.com




GMP Cytokine Market and Competition Outlook to 2031: Growing at 8.4% CAGR, Led by Bio-Techne, PeproTech, CellGenix Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “GMP Cytokine Market Report: Trends, Forecast and Competitive Analysis to 2031” has been added to ResearchAndMarkets.com’s offering.

The global GMP cytokine market is expected to grow with a CAGR of 8.4% from 2025 to 2031. The major drivers for this market are the increasing demand for immunotherapies, the rising adoption of personalized medicine, and the growing focus on cancer research. The future of the market looks promising with opportunities in the cell/gene therapy and tissue-engineered product markets.

• Within the type category, interleukin is expected to witness the highest growth over the forecast period.
• Within the application category, cell/gene therapy is expected to witness higher growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the GMP Cytokine Market

The GMP cytokine market is evolving as advanced therapeutics expand, focusing on personalized medications and innovative manufacturing techniques. Key trends include the move towards personalized medicine, bioprocess optimization, growth of contract manufacturing services, better delivery technologies, and the adoption of advanced analytics and AI. These trends are transforming the market into a technologically advanced sector prioritizing precision and efficiency.

Recent Developments in the GMP Cytokine Market

Recent developments include the shift to animal-free expression systems to enhance safety, expansion of commercial-scale production, regulatory harmonization, and strategic alliances. These factors increase reliability, safety, and accessibility while fostering efficient global collaboration in the GMP cytokine market.

Strategic Growth Opportunities in the GMP Cytokine Market

The market is poised for strategic growth within cell and gene therapy, cancer immunotherapy, regenerative medicine, vaccine development, and biosimilars. These opportunities leverage the unique benefits of GMP cytokines, emphasizing innovation and specialization in therapeutic applications.

GMP Cytokine Market Drivers and Challenges

Growth is driven by rising chronic diseases, expanding cell and gene therapy markets, technological advances, supportive regulatory environments, and increased R&D investments. Challenges include high manufacturing costs, stringent regulatory compliance, and supply chain risks. Navigating these factors will shape a dynamic and innovative market landscape.

Country-Wise Outlook for the GMP Cytokine Market

Countries are advancing in GMP cytokine production tailored to their economic and regulatory contexts. The US leads with robust R&D and regulatory support. China’s emphasis on local manufacturing boosts accessibility. Germany focuses on high-quality production and regulation. India and Japan invest in local R&D, aiding market growth through cost-efficiency and strategic focuses respectively.

Key Topics Covered

1. Executive Summary

2. Market Overview

2.1 Background and Classifications

2.2 Supply Chain

3. Market Trends & Forecast Analysis

3.1 Global GMP Cytokine Market Trends and Forecast

3.2 Industry Drivers and Challenges

3.3 PESTLE Analysis

3.4 Patent Analysis

3.5 Regulatory Environment

4. Global GMP Cytokine Market by Type

4.1 Overview

4.2 Attractiveness Analysis by Type

4.3 TNF: Trends and Forecast (2019-2031)

4.4 Interleukin: Trends and Forecast (2019-2031)

4.5 Growth Factor: Trends and Forecast (2019-2031)

4.6 Others: Trends and Forecast (2019-2031)

5. Global GMP Cytokine Market by Application

5.1 Overview

5.2 Attractiveness Analysis by Application

5.3 Cell/Gene Therapy: Trends and Forecast (2019-2031)

5.4 Tissue-Engineered Products: Trends and Forecast (2019-2031)

5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

6.1 Overview

6.2 Global GMP Cytokine Market by Region

7. North American GMP Cytokine Market

8. European GMP Cytokine Market

9. APAC GMP Cytokine Market

10. RoW GMP Cytokine Market

11. Competitor Analysis

11.1 Product Portfolio Analysis

11.2 Operational Integration

11.3 Porter’s Five Forces Analysis

11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

12.1 Value Chain Analysis

12.2 Growth Opportunity Analysis

12.2.1 Growth Opportunities by Type

12.2.2 Growth Opportunities by Application

12.3 Emerging Trends in the Global GMP Cytokine Market

12.4 Strategic Analysis

12.4.1 New Product Development

12.4.2 Certification and Licensing

12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

13.1 Competitive Analysis

13.2 Bio-Techne

13.3 PeproTech

13.4 CellGenix

13.5 Miltenyi Biotec

13.6 Cytiva

13.7 Lonza

13.8 ReproCELL

13.9 Sino Biological

13.10 Akron Biotech

13.11 Creative Bioarray

For more information about this report visit https://www.researchandmarkets.com/r/42l1pl

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Insights Into the Booming Peptide Cancer Vaccines Market 2025-2031: Key Trends & Opportunities in Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, and Other Applications – ResearchAndMarkets.com




Insights Into the Booming Peptide Cancer Vaccines Market 2025-2031: Key Trends & Opportunities in Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, and Other Applications – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Peptide Cancer Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031” has been added to ResearchAndMarkets.com’s offering.

The global peptide cancer vaccine market is expected to grow with a CAGR of 19.8% from 2025 to 2031. The major drivers for this market are the increasing demand for targeted cancer therapies, the rising government funding for cancer research, and the growing focus on personalized cancer treatments.

The future of the global peptide cancer vaccine market looks promising with opportunities in the breast cancer, lung cancer, melanoma, and prostate cancer markets.

Key Highlights by Segment

• Within the type category, galinpepimut-S is expected to witness the highest growth over the forecast period.
• Within the application category, breast cancer is expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Peptide Cancer Vaccine Market

The peptide cancer vaccine market is transforming with trends aimed at overcoming past limitations and enhancing personalized medicine. Key trends include developing personalized neoantigen vaccines, utilizing combination therapies with checkpoint inhibitors, and advancing adjuvant and delivery systems. The integration of AI and big data is streamlining the identification of effective peptide candidates, accelerating R&D processes, and improving patient outcomes.

Recent Developments in the Peptide Cancer Vaccine Market

Recent developments in the peptide cancer vaccine market include late-stage clinical trials of personalized vaccines, strategic partnerships between major pharmaceutical and biotech companies, and the introduction of advanced adjuvant technologies. The market is witnessing increased FDA approvals and the expansion of target indications to encompass a broader range of cancers. These advancements foster a professional and technology-driven industry ecosystem.

Strategic Growth Opportunities in the Peptide Cancer Vaccine Market

Significant strategic growth opportunities are emerging in personalized medicine, combination therapies, and the development of adjuvant and delivery partnerships. The growing focus on early-stage clinical trials and emerging economies presents more growth avenues. Companies are encouraged to diversify and specialize in unique applications to cater to various patient demographics and healthcare providers.

Peptide Cancer Vaccine Market Drivers and Challenges

The market is driven by factors such as rising cancer incidence, advancements in genomic sequencing, and a favorable regulatory environment. Increased investments in immuno-oncology also bolster growth. However, challenges like low immunogenicity, high development costs, and tumor-induced immunosuppression pose significant obstacles. Addressing these challenges is crucial for maintaining a competitive edge.

Country-Wise Outlook for the Peptide Cancer Vaccine Market

• United States: Leads with R&D investments in personalized vaccines and combination therapies.
• China: Expands rapidly with government support and growing public-private partnerships.
• Germany: Focuses on innovative vaccine formulations and universal approaches.
• India: Sees growth through affordable and accessible treatments.
• Japan: Invests in AI and data-driven developments with a focus on safety and efficacy.

Key Topics Covered

1. Executive Summary

2. Market Overview

2.1 Background and Classifications

2.2 Supply Chain

3. Market Trends & Forecast Analysis

3.1 Global Peptide Cancer Vaccine Market Trends and Forecast

3.2 Industry Drivers and Challenges

3.3 PESTLE Analysis

3.4 Patent Analysis

3.5 Regulatory Environment

4. Global Peptide Cancer Vaccine Market by Type

4.1 Overview

4.2 Attractiveness Analysis by Type

4.3 ITK-1: Trends and Forecast (2019-2031)

4.4 GRN-1201: Trends and Forecast (2019-2031)

4.5 TPIV200: Trends and Forecast (2019-2031)

4.6 TPIV110: Trends and Forecast (2019-2031)

4.7 UV1: Trends and Forecast (2019-2031)

4.8 Galinpepimut-S: Trends and Forecast (2019-2031)

4.9 TARP 27-35: Trends and Forecast (2019-2031)

4.10 HER-Vaxx: Trends and Forecast (2019-2031)

4.11 Others: Trends and Forecast (2019-2031)

5. Global Peptide Cancer Vaccine Market by Application

5.1 Overview

5.2 Attractiveness Analysis by Application

5.3 Breast Cancer: Trends and Forecast (2019-2031)

5.4 Lung Cancer: Trends and Forecast (2019-2031)

5.5 Melanoma: Trends and Forecast (2019-2031)

5.6 Prostate Cancer: Trends and Forecast (2019-2031)

5.7 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

6.1 Overview

6.2 Global Peptide Cancer Vaccine Market by Region

7. North American Peptide Cancer Vaccine Market

8. European Peptide Cancer Vaccine Market

9. APAC Peptide Cancer Vaccine Market

10. RoW Peptide Cancer Vaccine Market

11. Competitor Analysis

11.1 Product Portfolio Analysis

11.2 Operational Integration

11.3 Porter’s Five Forces Analysis

11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

12.1 Value Chain Analysis

12.2 Growth Opportunity Analysis

12.2.1 Growth Opportunities by Type

12.2.2 Growth Opportunities by Application

12.3 Emerging Trends in the Global Peptide Cancer Vaccine Market

12.4 Strategic Analysis

12.4.1 New Product Development

12.4.2 Certification and Licensing

12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

13.1 Competitive Analysis

13.2 Boston Biomedical

13.3 Ultimovacs

13.4 BrightPath Biotherapeutics

13.5 TapImmune

13.6 Immatics

13.7 Sellas

13.8 Imugene

13.9 VAXON Biotech

13.10 Generex Biotechnology

13.11 ISA Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/r/5nxfls

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Anova Launches Free AI-enabled Clinical Trial Patient Matching Solution as Part of a Global Just-in-time Research Network




Anova Launches Free AI-enabled Clinical Trial Patient Matching Solution as Part of a Global Just-in-time Research Network

• Anova launches a free AI-enabled patient matching solution that uses proprietary algorithms to connect patients to 200,000+ open clinical trials with high-confidence eligibility matching
• The AnovaOS^® platform speeds trial enrollment by automating screening, integrating into existing study coordination workflows, and enabling participation in a global just-in-time research network
• By removing cost barriers, Anova expands access to advanced research technology, strengthens collaboration across 60,000+ research sites and 15,000+ sponsors, and helps bring promising new therapies to patients faster

LONDON & CHICAGO–(BUSINESS WIRE)–#AI–Anova Enterprises, Inc. (Anova), a technology-enabled CRO dedicated to improving the conduct of clinical trials, has today announced the launch of its new AI-enabled patient matching solution as part of a global just-in-time research network and clinical trial infrastructure. The solution matches patients to open and accruing clinical trials and promising investigational products for compassionate use. The platform, available at no cost to participating research sites, accelerates trial enrollment by using AI and proprietary algorithms to identify patients who meet eligibility criteria with a high degree of certainty – matching demographic, molecular, and clinical history data to structured elgibility criteria from across 200,000+ open and accruing clinical trials.

Clinical trial enrollment remains one of the greatest challenges in drug development, with nearly 80% of studies experiencing delays due to recruitment difficulties. This new offering helps to address that barrier by providing research teams with an easy-to-use solution that integrates seamlessly into existing clinical workflows, streamlining the process of screening patients for trials.

The AnovaOS^® SaaS solution streamlines access for those involved in research, accelerates throughput of new therapies, and provides a framework for collaboration, quality evidence generation and scientific insight. The platform enables clinical trial sponsors to connect with over 60,000 research-ready clinical research sites globally. Sites are increasingly using the platform to identify clinical trial opportunities for their patients and practices.

Key features of the patient matching solution include:

• Automated eligibility screening against trial protocols.
• Secure, privacy-protected data handling to ensure patient confidentiality.
• Real-time updates on available trials and criteria changes.
• Scalable access for sites ranging from large academic centers to community practices.

“By making this solution free to access, we are empowering research sites of all sizes to connect the right patients with the right studies when treatment decisions are being made,” said Christopher Beardmore, CEO and Co-founder of Anova. “The only way to present clinical trial options to patients is when the decision to select the next line of therapy is being made. That cannot be done when study teams rely on medical record review, pathology results and potential patient lists. Patients are lost to study (and lose access to promising new treatments) when that approach is used. The AnovaOS solution not only provides a study matching capability, but supports a global just-in-time network to enable access to any investigational product just-in-time, either through a clinical trial or compassionate use.”

By removing cost barriers, Anova aims to broaden access to cutting-edge technology for clinical sites, foster more inclusive participation in research, help sponsors and investigators reach enrollment goals and bring promising new treatments more quickly to patients in need.

To find out more, contact info.us@anovaevidence.com.

About Anova

Anova Enterprises, Inc. (Anova) is a technology-enabled concierge research organization committed to accelerating clinical development for start-up biopharmaceutical companies utilizing the company’s proprietary technology platform (AnovaOS^®). For more information, please visit www.anovaevidence.com.

Chris Beardmore, Co-Founder and CEO

chris@anovaevidence.com

Martin Walsh, Co-Founder and President

Anova Enterprises, Inc.

martin@anovaevidence.com

www.anovaevidence.com
Twitter feed at @anovaevidence

Follow Anova at www.linkedin.com/company/anovaevidence

Contacts

Anova Enterprises, Inc.
Woodfield Preserve, 10 N. Martingale Road, Suite 560

Schaumburg, IL 60173

(224) 218-2408

info.us@anovaevidence.com

Diabetic Neuropathy Market Report: Trends, Forecast and Competitive Analysis to 2031 – APAC Leads Industry Growth as Demand for Pain Management Soars – ResearchAndMarkets.com




Diabetic Neuropathy Market Report: Trends, Forecast and Competitive Analysis to 2031 – APAC Leads Industry Growth as Demand for Pain Management Soars – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Diabetic Neuropathy Market Report: Trends, Forecast and Competitive Analysis to 2031” has been added to ResearchAndMarkets.com’s offering.

The global diabetic neuropathy market is expected to grow with a CAGR of 5% from 2025 to 2031. The major drivers for this market are the increasing prevalence of diabetes worldwide, the rising awareness about neuropathic disorders, and the growing demand for effective pain management. The future of the global diabetic neuropathy market looks promising with opportunities in the online pharmacy, hospital pharmacy, and retail pharmacy markets.

Key Highlights by Segment

• Within the type category, subcutaneous is expected to witness the highest growth over the forecast period.
• Within the application category, online pharmacy is expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Diabetic Neuropathy Market

The diabetic neuropathy market is undergoing significant changes due to advancements in understanding nerve damage, improved treatment methodologies, and technological integration. Focus has shifted towards disease modification, with emerging interest in non-pharmacological treatments and personalized medicine. Emphasis on early diagnosis using novel biomarkers is also increasing, while digital health tools are gaining traction for better patient management.

Recent Developments in the Diabetic Neuropathy Market

Recent developments in the market include advances in gene therapy and medical devices, such as the FDA-approved spinal cord stimulation systems. There is a rise in novel drug candidates targeting various pathways for nerve damage and a push towards better diagnostic tools. Focus has also increased on managing autonomic neuropathy, highlighting improvements in diagnosis and treatment strategies.

Strategic Growth Opportunities in the Diabetic Neuropathy Market

Significant growth opportunities exist in pain management solutions, disease-modifying therapies, and diabetic foot ulcer prevention. The increasing prevalence of autonomic neuropathy presents opportunities for targeted diagnostics and treatments. Development of early diagnostic tools and screening programs is another area for potential growth, allowing for timely interventions and better patient outcomes.

Diabetic Neuropathy Market Drivers and Challenges

The factors responsible for driving the diabetic neuropathy market include:

• Rising Global Prevalence of Diabetes: The increasing diabetic population necessitates more treatments for neuropathy.
• Increasing Awareness and Diagnosis Rates: Improved awareness and diagnostics fuel treatment demand.
• Aging Population: Older adults are more susceptible to diabetes complications, expanding the patient base.
• Advances in Research and Development: Innovations in R&D provide more effective treatments.
• Unmet Medical Need for Disease-Modifying Therapies: Demand for therapies that address nerve damage prompts innovation.

Challenges in the diabetic neuropathy market include:

• Lack of Definitive Cure: Current therapies focus on symptom management, not cures.
• Late Diagnosis and Disease Progression: Delays in diagnosis hamper treatment effectiveness.
• High Cost of Novel Therapies: The expense of new therapies can limit access and adoption.

Country-Wise Outlook for the Diabetic Neuropathy Market

The market is progressing with innovative therapies, including gene therapies in the U.S. and neurostimulation devices in Japan. In China and India, the focus is shifting towards local R&D and improved healthcare infrastructures to handle DPN effectively. Germany emphasizes combining medicinal and non-medicinal treatments, reflecting a comprehensive approach to manage complications.

Key Topics Covered

1. Executive Summary

2. Market Overview

2.1 Background and Classifications

2.2 Supply Chain

3. Market Trends & Forecast Analysis

3.1 Global Diabetic Neuropathy Market Trends and Forecast

3.2 Industry Drivers and Challenges

3.3 PESTLE Analysis

3.4 Patent Analysis

3.5 Regulatory Environment

4. Global Diabetic Neuropathy Market by Type

4.1 Overview

4.2 Attractiveness Analysis by Type

4.3 Oral: Trends and Forecast (2019-2031)

4.4 Subcutaneous: Trends and Forecast (2019-2031)

4.5 Intravenous: Trends and Forecast (2019-2031)

5. Global Diabetic Neuropathy Market by Application

5.1 Overview

5.2 Attractiveness Analysis by Application

5.3 Online Pharmacies: Trends and Forecast (2019-2031)

5.4 Hospital Pharmacies: Trends and Forecast (2019-2031)

5.5 Retail Pharmacies: Trends and Forecast (2019-2031)

6. Regional Analysis

6.1 Overview

6.2 Global Diabetic Neuropathy Market by Region

7. North American Diabetic Neuropathy Market

8. European Diabetic Neuropathy Market

9. APAC Diabetic Neuropathy Market

10. RoW Diabetic Neuropathy Market

11. Competitor Analysis

11.1 Product Portfolio Analysis

11.2 Operational Integration

11.3 Porter’s Five Forces Analysis

11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

12.1 Value Chain Analysis

12.2 Growth Opportunity Analysis

12.2.1 Growth Opportunities by Type

12.2.2 Growth Opportunities by Application

12.3 Emerging Trends in the Global Diabetic Neuropathy Market

12.4 Strategic Analysis

12.4.1 New Product Development

12.4.2 Certification and Licensing

12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

13.1 Competitive Analysis

13.2 Pfizer

13.3 Janssen Pharmaceuticals

13.4 Eli Lilly and Company

13.5 ACTAVIS

13.6 Cephalon

13.7 MEDA Pharma

13.8 GlaxoSmithKline

13.9 NeuroMetrix

13.10 Johnson & Johnson Services

13.11 Novartis

For more information about this report visit https://www.researchandmarkets.com/r/ibhms4

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900